Literature DB >> 10319764

High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice.

D Lapointe1, N Brasseur, J Cadorette, C La Madeleine, S Rodrigue, J E van Lier, R Lecomte.   

Abstract

UNLABELLED: The aim of this study was to investigate the use of [18F]fluoro-2-deoxy-D-glucose (FDG) and a small-animal PET scanner to assess early tumor response after photodynamic therapy (PDT) in mice. PDT consists of intravenous administration of a photosensitizer that accumulates preferentially in tumor tissue, followed by local illumination of the tumor with red light. Two different photosensitizers were used: Photofrin (PII), which has been approved for clinical use, and disulfonated aluminum phthalocyanine (AIPcS), which is a second-generation drug. These drugs have been shown to induce tumor necrosis through different action mechanisms, i.e., mainly initial vascular stasis (PII) or direct tumor cell kill (AIPcS). FDG PET was used to follow both perfusion and metabolic activity in the tumor tissue.
METHODS: The study was performed using a mouse model implanted with two contralateral murine mammary tumors (5 mm diameter x 2.5 mm thickness) on the back. Only one tumor was subjected to PDT, whereas the other tumor served as a control. A total of 13 mice were studied, 1 without illumination, 3 at 30 min and 3 at 2 h after PDT with both PII-PDT and AIPcS-PDT. Dynamic PET imaging of the mice, which were placed in pairs in a prostate position parallel to the transaxial planes of the Sherbrooke animal PET scanner, was performed after a bolus injection of 11 MBq (300 microCi) FDG. Blood samples were collected concurrently from 1 mouse during each study using an automated microvolumetric blood sampler.
RESULTS: Analysis of the tumor time-activity curves showed that (a) scans during the first 3 min provided an estimate of tumor perfusion, as confirmed by the blood samples; (b) the tumor FDG uptake after 15 min was a direct measurement of tumor metabolism clearly demonstrating the relative efficacy of the two PDT drugs; and (c) the tumor tracer concentration in the interval 3-15 min after FDG injection is an appropriate indicator of the different mechanisms of tumor necrosis through indirect vascular stasis (PII) or direct cell kill (AIPcS).
CONCLUSION: This pilot study confirmed the feasibility of using dynamic in vivo PET imaging for assessing early tumor response to PDT in mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10319764

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

Review 1.  Imaging and photodynamic therapy: mechanisms, monitoring, and optimization.

Authors:  Jonathan P Celli; Bryan Q Spring; Imran Rizvi; Conor L Evans; Kimberley S Samkoe; Sarika Verma; Brian W Pogue; Tayyaba Hasan
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

2.  In Vivo Small Animal Imaging for Early Assessment of Therapeutic Efficacy of Photodynamic Therapy for Prostate Cancer.

Authors:  Baowei Fei; Hesheng Wang; Xiang Chen; Joseph Meyers; John Mulvihill; Denise Feyes; Nancy Edgehouse; Jeffrey L Duerk; Thomas G Pretlow; Nancy L Oleinick
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2007-03-29

3.  Prostate PDT dosimetry.

Authors:  Timothy C Zhu; Jarod C Finlay
Journal:  Photodiagnosis Photodyn Ther       Date:  2006-10-19       Impact factor: 3.631

4.  Choline PET for monitoring early tumor response to photodynamic therapy.

Authors:  Baowei Fei; Hesheng Wang; Chunying Wu; Song-mao Chiu
Journal:  J Nucl Med       Date:  2009-12-15       Impact factor: 10.057

5.  Choline Molecular Imaging with Small-animal PET for Monitoring Tumor Cellular Response to Photodynamic Therapy of Cancer.

Authors:  Baowei Fei; Hesheng Wang; Chunying Wu; Joseph Meyers; Liang-Yan Xue; Gregory Maclennan; Mark Schluchter
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2009-02-27

Review 6.  PET-based molecular imaging in neuroscience.

Authors:  A H Jacobs; H Li; A Winkeler; R Hilker; C Knoess; A Rüger; N Galldiks; B Schaller; J Sobesky; L Kracht; P Monfared; M Klein; S Vollmar; B Bauer; R Wagner; R Graf; K Wienhard; K Herholz; W D Heiss
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-23       Impact factor: 9.236

7.  TLD assessment of mouse dosimetry during microCT imaging.

Authors:  Said Daibes Figueroa; Christopher T Winkelmann; H William Miller; Wynn A Volkert; Timothy J Hoffman
Journal:  Med Phys       Date:  2008-09       Impact factor: 4.071

8.  The evolving role of nuclear molecular imaging in cancer.

Authors:  Ka Kurdziel; G Ravizzini; By Croft; Jl Tatum; Pl Choyke; H Kobayashi
Journal:  Expert Opin Med Diagn       Date:  2008-07

9.  Unique diagnostic and therapeutic roles of porphyrins and phthalocyanines in photodynamic therapy, imaging and theranostics.

Authors:  Leanne B Josefsen; Ross W Boyle
Journal:  Theranostics       Date:  2012-10-04       Impact factor: 11.556

10.  Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.

Authors:  A T Byrne; A E O'Connor; M Hall; J Murtagh; K O'Neill; K M Curran; K Mongrain; J A Rousseau; R Lecomte; S McGee; J J Callanan; D F O'Shea; W M Gallagher
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.